Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT03922607 Completed - Psoriasis Clinical Trials

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

Start date: June 11, 2019
Phase: Phase 1
Study type: Interventional

This is a study to evaluate pharmacokinetics (PK), safety and tolerability of ABBV-157 in healthy volunteers and in participants with chronic plaque psoriasis, and to evaluate the efficacy of ABBV-157 in the participants with psoriasis. This study consists of two substudies. Substudy 1 is a randomized, double-blind, placebo-controlled evaluation of multiple ascending oral doses of ABBV-157 in healthy adult volunteers. Substudy 2 is a randomized, double-blind, placebo-controlled study in which participants with moderate to severe chronic plaque psoriasis will be administered multiple oral doses of ABBV-157.

NCT ID: NCT03898583 Completed - Psoriasis Vulgaris Clinical Trials

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

Start date: April 15, 2019
Phase: Phase 1
Study type: Interventional

To assess safety, tolerability and pharmacodynamics effect of treatment with microarray patches containing calcipotriol and betamethasone dipropionate.

NCT ID: NCT03897088 Completed - Scalp Psoriasis Clinical Trials

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

Start date: March 29, 2019
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.

NCT ID: NCT03895372 Completed - Psoriasis Clinical Trials

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Start date: June 27, 2019
Phase: Phase 2
Study type: Interventional

This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical development of PF-06826647.

NCT ID: NCT03894579 Completed - Plaque Psoriasis Clinical Trials

Autologous Natural Killer Cells in Subjects With Plaque Psoriasis

Start date: July 18, 2019
Phase: Phase 1
Study type: Interventional

This is a non-randomized, dose escalating and open-labeled clinical trial to evaluate the safety of autologous natural killer cell (NK) infusions (IV) of "SNK01" in adults with plaque psoriasis. The primary objective of this study is to investigate the safety and tolerability of four infusions of "SNK01" in subjects with plaque psoriasis. Secondary objective is preliminary efficacy of "SNK01" in subjects with plaque psoriasis.

NCT ID: NCT03885089 Completed - Psoriasis Vulgaris Clinical Trials

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Start date: October 21, 2019
Phase:
Study type: Observational

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under actual status of use.

NCT ID: NCT03880357 Completed - Scalp Psoriasis Clinical Trials

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

Start date: October 22, 2018
Phase: Phase 1
Study type: Interventional

To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of scalp psoriasis.

NCT ID: NCT03875508 Completed - Psoriasis Clinical Trials

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Start date: June 4, 2019
Phase: Phase 3
Study type: Interventional

The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of adult participants with moderate to severe plaque psoriasis.

NCT ID: NCT03875482 Completed - Psoriasis Clinical Trials

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Start date: May 13, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.

NCT ID: NCT03873415 Completed - Psoriasis Clinical Trials

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

Start date: January 25, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males